07.31.24 | SLAS Technology
2024
06.23.24 | ACS National Medicinal Chemistry Symposium
04.10.24 | Journal of Medicinal Chemistry
04.09.24 | AACR
Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors
Genome-wide drug anchor screens identify CAAP1 and AKAP17A as regulators of PRMT5 inhibitor sensitivity
TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress
04.04.24 | Applied Pharmaceutical Chemistry
03.20.24 | ACS National Meeting
03.11.24 | GRC DNA Damage, Mutation and Cancer
2023
10.13.23 | AACR-NCI-EORTC
MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies
Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer models
TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair
Cancer-specific AI identifies multi-modal biomarkers of therapeutic response for 1,951 drugs including TNG348, a highly selective USP1 inhibitor
08.16.23 | ACS National Meeting
04.18.23 | AACR
TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors
TNG348 is a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut and HRD+ cancers
TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models
TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers
02.01.23 | AACR Molecular Cancer Therapeutics
2022
11.10.22 | SITC
TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11
In vivo CRISPR screens identify HDAC1 as an immune sensitizer reversing immune resistance driven by STK11 loss
Whole genome CRISPR-Cas9 screens in a cancer cell line panel co-cultured with antigen-specific cytotoxic CD8 T cells are a powerful engine for immuno-oncology drug target discovery
Leveraging CRISPR-Cas9 screening platform for discovery of novel tumor intrinsic phagocytosis modulators
10.27.22 | EORTC-NCI-AACR
Biochemical characterization of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer
TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors
09.08.22 | AACR Cancer Research
04.08.22 | AACR
TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies
USP1 inhibitor synthetic lethality in BRCA1/2 mutant cancer is driven by PCNA ubiquitination
UMIBB: A novel nonparametric Bayesian method improves robustness and sensitivity of analysis in pooled CRISPR Cas9 screens leveraging unique molecular identifiers
2021
10.12.21 | AACR-NCI-EORTC
TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regression in MTAP-deleted xenograft models across histologies
VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma
CRISPR screens identify sensitizers to trametinib in KRAS mutant cancer cell lines
Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC
Isogenic CRISPR anchor screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer
2020
10.13.20 | ASCPT Clinical and Translational Science
2019
11.15.19 | Nature Reviews Drug Discovery